

A majority of SynAct Pharma's Board and management have acquired shares with a value of more than SEK 1 million

SynAct Pharma AB (publ), "SynAct", (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that members of the board and senior executives have within the past few days acquired 61,525 shares in SynAct with a total value of more than SEK 1 million.

Specifically, the Chairman of the Board, Anders Kronborg, and Board Member Sten R. Sörensen have acquired in total 9,198 number and the CEO Jeppe Øvlesen, CFO Björn Westberg, CSO Thomas Jonassen, and COO Thomas Boesen, have acquired 48,747 shares. Related parties, to management, have acquired 3,580 shares.

"SynAct earlier in June announced the refined development strategy with two tracks: 1) Early intervention in autoimmune and inflammatory diseases with primary focus on rheumatoid Arthritis (RA) and 2) Host-directed treatment in viral infections. We are very dedicated to this strategy and we strongly believe it will enable a successful outcome for SynAct," said Anders Kronborg, Chairman of the Board.

"Following a successful financing round, we are in a favorable position to execute on our plans and push forward. It is a pleasure to see the strong commitment in the management group and to have the support of our board," said CEO Jeppe Øvlesen.

For further information, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: <https://synactpharma.com/>.

Attachments

[A majority of SynAct Pharma's Board and management have acquired shares with a value of more than SEK 1 million](#)